Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER)

The American Journal of Cardiology
Stephen J NichollsPhilip Barter

Abstract

Statins are the most commonly prescribed agents for lowering levels of low-density lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statins, the impact of increasing dose has not been fully elucidated. An individual patient data pooled analysis was performed of 32,258 patients in studies comparing the efficacy of rosuvastatin with that of atorvastatin or simvastatin. The impact of increasing dose on lowering LDL cholesterol, triglycerides, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B was investigated. Doubling the dose of each statin was accompanied by a 4% to 7% greater degree of lowering of all atherogenic lipids. A stronger correlation was observed between changes in LDL cholesterol and non-HDL cholesterol (r = 0.92, p <0.001) or apolipoprotein B (r = 0.76, p <0.001) than triglycerides (r = 0.14, p <0.001). On multivariate analysis, baseline lipid level (p <0.0001) and increasing statin dose (p <0.0001) were strong predictors of achieving treatment goals in high-risk patients. Increasing age was a strong independent predictor of achieving goal for all atherogenic lipids (p <0.0001). Achieving LDL cholesterol goals was also more lik...Continue Reading

References

Mar 1, 2002·Evaluation & the Health Professions·Lesley A Stewart, Jayne F Tierney
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Jan 22, 2004·The European Journal of General Practice·Carlos BrotonsUNKNOWN International Society of Behavioral Medicine
Aug 13, 2004·The New England Journal of Medicine·Pim van der HarstDirk J van Veldhuisen

❮ Previous
Next ❯

Citations

Aug 28, 2013·Wiener medizinische Wochenschrift·Max PichlerRaimund Weitgasser
Nov 17, 2011·The New England Journal of Medicine·Stephen J NichollsSteven E Nissen
Jun 29, 2010·Current Opinion in Lipidology·Lorenzo Arnaboldi, Alberto Corsini
Jan 13, 2011·American Journal of Physiology. Endocrinology and Metabolism·Alexander P TuckowLeonard S Jefferson
Jul 17, 2013·Cardiovascular Diabetology·Henry Ginsberg
Jul 17, 2013·Cardiovascular Diabetology·Luis Masana
Oct 6, 2010·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·James P McCormackAdil S Virani
Mar 22, 2014·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Clotilde MoralesLluís Vila
Jul 23, 2014·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Carlos Guijarro-HerraizAlberto Cordero-Fort
Nov 13, 2014·The New England Journal of Medicine·Martin J LandrayJane Armitage
Apr 5, 2011·International Journal of Hypertension·Enrique C Morales-VillegasCarlo Briguori
Oct 2, 2012·Canadian Journal of Physiology and Pharmacology·Grant Pierce
Sep 8, 2012·Journal of Medical Economics·Vivencio BarriosConcha Alvarez Sanz
Jul 9, 2011·Expert Opinion on Pharmacotherapy·Theodosios D Filippatos, Moses S Elisaf
Nov 26, 2010·Expert Opinion on Drug Metabolism & Toxicology·Miao HuBrian Tomlinson
Oct 21, 2010·Expert Opinion on Pharmacotherapy·Vasilios G AthyrosDimitri P Mikhailidis
Nov 25, 2014·Current Medical Research and Opinion·Fotios BarkasEvangelos Liberopoulos
Jan 23, 2016·Journal of Clinical Pharmacy and Therapeutics·H-S KimI Y Choi
Nov 16, 2013·The American Journal of Cardiology·Hisato TakagiUNKNOWN ALICE (All-Literature Investigation of Cardiovascular Evidence) Group
Sep 18, 2013·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Juan Pedro-BotetUNKNOWN En Nombre del Grupo de Investigadores EDICONDIS-ULISEA
Jun 19, 2012·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·B W KarlsonS J Nicholls
Dec 14, 2011·Atherosclerosis. Supplements·Philip Barter
Oct 22, 2011·Biochimica Et Biophysica Acta·A C I BoullartA F Stalenhoef
Aug 8, 2015·American Journal of Respiratory and Critical Care Medicine·Keith R WalleyJohn H Boyd
Jun 21, 2015·Contemporary Clinical Trials·Mark SimmondsLesley Stewart
Mar 15, 2016·Current Atherosclerosis Reports·P Elliott Miller, Seth S Martin
Sep 8, 2015·Journal of Clinical Lipidology·Rae-Ellen W Kavey
Aug 25, 2012·Evidence-based Complementary and Alternative Medicine : ECAM·Ming Wai HungSimon Ming Yuen Lee
Sep 4, 2014·European Heart Journal·Lorenz RäberUNKNOWN IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416)
Mar 21, 2015·International Journal of Cardiology·Yafeng LiSihai Zhao

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.